Assessment of clinical neurophysiological biomarkers for the differentiation of neurodegenerative disease versus non-neurological disorder in patients with mild cognitive impairment. - Clinical neurophysiological biomarkers in mild cognitive impairment.

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Observational non invasive

Sponsor

•1\. Male or female subject of \>\= 45 years of age at screening.
•2\. Cognitive disorders defined as mild cognitive impairment diagnosed by a
•neurologist, suspected due to neurodegenerative disease or non\-neurological
•disorder (e.g. psychiatric disorders).
•3\. Willing and able to voluntary sign the informed consent form (ICF).
•4\. Willing and able to communicate with the investigator and site staff and to
•comply with the study requirements and visits.

•1\. Clinically significant findings as determined by medical history taking,
•physical examination, ECG and vital signs, which, in the opinion of the
•Investigator, does not allow study participation.
•2\. Any previously diagnosed dementia or other neurodegenerative disease at or
•prior to screening
•3\. Any current, clinically significant, known neurological cause of cognitive
•disorders at or prior to screening.
•4\. Inability to willfully sign the informed consent document, supported by an
•MMSE \< 24 at screening. Exceptionally, patients with an MMSE \< 24 can be
•included only if the rationale is clearly documented by the investigator (i.e.,